The Trump administration is intensifying its scrutiny of pharmaceutical advertising, with the FDA set to issue cease-and-desist notices and warnings to companies for misleading direct-to-consumer ads. A presidential memorandum directs increased enforcement to ensure transparency and accuracy, addressing concerns about deceptive practices and inadequate disclosure of side effects.